Litigation Details for CELGENE CORPORATION v. MSN LABORATORIES PRIVATE LIMITED (D.N.J. 2022)

« Back to Dashboard

CELGENE CORPORATION v. MSN LABORATORIES PRIVATE LIMITED (D.N.J. 2022)

Docket		Date Filed	2022-04-06
Court	District Court, D. New Jersey	Date Terminated	2022-06-15
Cause	35:271 Patent Infringement	Assigned To	Esther Salas
Jury Demand	None	Referred To	Michael A. Hammer
Patents	10,555,939; 8,198,262; 8,673,939; 8,735,428; 8,828,427; 9,993,467
Link to Docket	External link to docket

Details for CELGENE CORPORATION v. MSN LABORATORIES PRIVATE LIMITED (D.N.J. 2022)

Date Filed	Document No.	Description	Snippet	Link To Document
2022-04-06				External link to document
2022-04-06	16	Order of Dismissal	; 9,993,467; and 10,555,939. 4. Until expiration of the Patents-in-Suit, MSN, including…this Consent Judgment, the term “Patents-in-Suit” shall mean U.S. Patent Nos. 8,198,262; 8,673,939; 8,735,428…purposes of this action only. Until expiration of the Patents-in-Suit, MSN, including any of its successors and… and assigns, is enjoined from infringing the Patents-in-Suit, on its own part or through any third party…affirmative defenses and demands pertaining to the Patents-in-Suit are hereby dismissed with prejudice and	External link to document

Celgene Corporation v. MSN Laboratories: Litigation Summary, Patent Scope, and Generic Entry Risk

Last updated: October 15, 2026

Celgene Corporation v. MSN Laboratories Private Limited, Case No. 2:22-cv-01993, is a Hatch-Waxman patent action filed in the U.S. District Court for the District of New Jersey concerning MSN Laboratories’ abbreviated new drug application for generic pomalidomide capsules, the generic equivalent of Celgene’s Pomalyst product. The dispute concerns patent protection for pomalidomide, a multiple-myeloma therapy marketed by Celgene and later within Bristol Myers Squibb’s portfolio.

The case presents a conventional ANDA litigation structure: Celgene alleged that MSN’s Paragraph IV certification created an artificial act of infringement under 35 U.S.C. § 271(e)(2), while MSN sought regulatory approval to market generic pomalidomide before the asserted patent rights expired. The commercial significance is tied to Pomalyst’s high-value multiple-myeloma franchise and the limited number of approved manufacturers capable of supplying the product.

What drug is at issue in Celgene v. MSN Laboratories?

The product at issue is Pomalyst, whose active ingredient is pomalidomide.

Product	Active ingredient	Dosage form	Reference sponsor	Generic pathway
Pomalyst	Pomalidomide	Oral capsules	Celgene Corporation	ANDA under the Hatch-Waxman Act
Proposed MSN product	Pomalidomide	Oral capsules	MSN Laboratories Private Limited	Abbreviated new drug application

Pomalidomide is an immunomodulatory agent used primarily in combination regimens for patients with multiple myeloma who have received prior therapies. The product is not a biologic. The relevant regulatory pathway is therefore an ANDA, not a biosimilar application under the Biologics Price Competition and Innovation Act.

Pomalidomide is commercially related to lenalidomide and thalidomide, but those products have separate patent estates, clinical indications, and generic-entry histories.

When was Celgene v. MSN Laboratories filed?

Celgene filed the action in 2022 in the District of New Jersey under Case No. 2:22-cv-01993. The filing followed MSN’s Paragraph IV certification concerning patents listed for Pomalyst in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book.

Under the Hatch-Waxman framework, Celgene had 45 days after receiving MSN’s Paragraph IV notice to sue. The filing of the action triggered an automatic 30-month stay of FDA approval for the relevant ANDA, subject to earlier termination or modification by court order. The stay is governed by 21 U.S.C. § 355(j)(5)(B)(iii).

Key procedural framework

Event	Legal consequence
MSN submitted an ANDA	Sought approval for generic pomalidomide capsules
MSN delivered a Paragraph IV notice	Asserted that listed Celgene patents were invalid, unenforceable, or not infringed
Celgene filed suit	Created an artificial infringement claim under 35 U.S.C. § 271(e)(2)
Litigation commenced within 45 days	Triggered the statutory 30-month FDA approval stay
Final judgment or settlement	Could establish the effective generic-entry date

What patents protect Pomalyst and pomalidomide?

Pomalidomide has several layers of potential protection. The portfolio includes patents directed to the active compound, pharmaceutical compositions, dosing regimens, and treatment methods. The practical value of each patent depends on whether it is listed for the relevant product, asserted against the MSN ANDA, and able to withstand invalidity and infringement challenges.

Publicly available FDA and patent records identify multiple Celgene-related pomalidomide patent families, including patents directed to:

• Pomalidomide compounds and chemical intermediates.
• Pharmaceutical compositions containing pomalidomide.
• Treatment of multiple myeloma.
• Dosing schedules and administration methods.
• Combination therapy with other anti-myeloma agents.
• Risk-management and controlled-distribution systems associated with immunomodulatory drugs.

Patents commonly associated with the Pomalyst estate include U.S. Patent Nos. 6,315,720, 6,561,976, 8,198,262, 8,673,939, 9,376,405, and related continuation or divisional patents. The precise patents at issue in the MSN action must be read from the operative complaint, amended pleadings, and claim-construction record rather than inferred solely from the broader Orange Book listing.

Why the patent-number distinction matters

The Orange Book may contain patents that are not asserted in every ANDA case. A patent may be:

1. Listed for the reference product but not asserted against a particular ANDA.
2. Asserted only against certain dosage strengths.
3. Relevant to a method-of-use certification rather than the product composition.
4. Subject to a covenant not to sue or settlement limitation.
5. Expired or close to expiration when the case is filed.

For market-entry analysis, the controlling set is the asserted patent group combined with any settlement or judgment governing MSN’s launch date.

What was MSN Laboratories’ likely Paragraph IV position?

MSN’s Paragraph IV position placed the validity, enforceability, or infringement of the asserted Pomalyst patents in dispute. In a case involving generic pomalidomide, the primary defenses typically include:

• The asserted claims are invalid for anticipation under 35 U.S.C. § 102.
• The claims are obvious under 35 U.S.C. § 103.
• The ANDA product does not infringe the asserted composition claims.
• The proposed label does not induce infringement of the asserted method-of-use claims.
• The asserted claims are unenforceable because of inequitable conduct or other equitable defenses.
• The patent claims do not cover the specific dosage strengths or formulation described in the ANDA.

The strongest generic defenses often arise against later-issued method-of-use patents. A generic manufacturer can sometimes avoid infringement by using a “skinny label” that omits patented indications, although that strategy is more difficult where the patented use is central to the product’s label or where the reference label encourages the patented regimen.

What is the Orange Book status of Pomalyst?

Pomalyst is an FDA-approved small-molecule drug with Orange Book-listed patents. Its regulatory exclusivity is therefore controlled by a combination of:

• FDA statutory exclusivity.
• Orange Book patent listings.
• Paragraph IV litigation.
• Settlement terms.
• Any pediatric exclusivity extension.
• Expiration dates for compound, formulation, and method-of-use patents.

Pomalyst received FDA approval in 2013. New chemical entity exclusivity for the active ingredient would have run for five years from approval, subject to the statutory rules applicable to the approval date. That regulatory exclusivity is separate from patent protection and would not independently block a later ANDA once the relevant exclusivity period ended.

Regulatory and patent protection are different

Protection	Function	Relevance to MSN
NCE exclusivity	Blocks certain ANDA submissions during the statutory period	Likely expired before the 2022 case
Orange Book patents	Permit patent litigation and a potential approval stay	Central to the case
Pediatric exclusivity	Adds six months to qualifying patent or exclusivity periods	Relevant only if granted for the listed patents
REMS or controlled distribution	Manages safety risks	May create operational barriers but does not replace patent protection
Patent settlement	Establishes agreed entry conditions	Potentially decisive if the case settled

When does Pomalyst lose exclusivity?

Pomalyst does not have one single “loss of exclusivity” date. The answer depends on which layer of exclusivity is being evaluated.

The original chemical-entity exclusivity period expired years before the 2022 litigation. Later market protection depended on patent claims covering pomalidomide treatment, formulations, dosing, and related uses. Certain Pomalyst patents have been reported with expiration dates extending into the late 2020s or early 2030s, depending on the patent family and any patent-term adjustment or pediatric extension.

A generic entrant may therefore obtain FDA approval before the latest patent expiration if:

• The generic wins the litigation.
• The asserted patents are invalidated.
• Celgene dismisses the action.
• A settlement grants an authorized or licensed entry date.
• The generic uses a label that avoids an enforceable method-of-use claim.

The latest Orange Book-listed patent date should not be treated as the guaranteed commercial launch date. Launch can occur earlier under a settlement or later because of manufacturing, regulatory, or commercial constraints.

What patent litigation affects MSN’s generic pomalidomide launch?

The principal litigation risk is whether Celgene can maintain enforceable claims covering MSN’s ANDA product or its proposed labeling. The case is important because Pomalyst’s patent estate has multiple claim categories.

Formulation and composition claims

Composition claims can present a substantial barrier when they cover the drug product itself rather than a single use. If the asserted claim reads directly on the generic capsule, a successful infringement finding can block approval until patent expiry unless the generic prevails on invalidity.

The risk is lower where the patent covers a narrow excipient combination, manufacturing parameter, or formulation limitation not present in MSN’s ANDA.

Method-of-use claims

Method-of-use claims may cover treatment of multiple myeloma, dosing frequency, combination therapy, or treatment of a specified patient population. MSN could contest infringement by relying on a label that omits the patented use. Celgene could respond that the proposed label, prescribing information, or product design encourages use of the patented method.

Manufacturing and process patents

Process patents generally create less direct ANDA risk than product or treatment patents because the ANDA may not disclose every manufacturing detail and the generic can potentially use a noninfringing process. Process patents remain relevant, however, if Celgene can obtain discovery into MSN’s manufacturing operations or if the process is required to produce the claimed formulation.

How strong is Celgene’s patent estate for Pomalyst?

Celgene’s estate appears stronger as a layered portfolio than as a single blocking patent. Its commercial durability depends on the interaction of compound, formulation, and method-of-use claims.

Patent category	Strategic value	Generic challenge profile
Core compound patent	Highest when unexpired	Often attacked through validity and priority arguments
Composition patent	High if it reads on the capsule	Infringement may be straightforward
Treatment patent	Variable	Label-splitting and induced-infringement defenses
Dosing patent	Variable to high	Depends on label language and clinical use
Process patent	Moderate	Noninfringing manufacturing route may be available
REMS-related rights	Operational value	Usually not a substitute for patent exclusivity

The age of the foundational pomalidomide patents weakens the core chemical exclusivity position. Later-issued patents can extend commercial protection, but they tend to face stronger obviousness and written-description challenges because the underlying active ingredient and therapeutic class were already known.

The most defensible claims are generally those tied to a specific, clinically necessary regimen or a formulation limitation that is difficult to design around. Broad claims that merely restate the known use of pomalidomide face greater vulnerability under obviousness challenges.

Which companies are challenging Pomalyst patents?

MSN Laboratories is one of several generic manufacturers that have pursued or may pursue approval for pomalidomide. The competitive field includes large generic companies with experience in complex capsules, oncology products, and controlled-distribution requirements.

Potential competitors include manufacturers that have filed ANDAs or participated in related Pomalyst patent disputes. The existence of a separate challenge does not establish that a company can launch. Each applicant faces its own certification, litigation, settlement, manufacturing, and FDA approval profile.

Competition is also affected by authorized generic arrangements. Celgene or its successor could license or authorize a generic supplier before patent expiry, reducing the expected market share of an independent Paragraph IV entrant.

What was the litigation status and settlement risk?

The public case record should be evaluated for the following dispositive events:

• Answer to the complaint.
• Counterclaims for patent invalidity or unenforceability.
• Claim-construction briefing.
• Discovery orders.
• Summary-judgment motions.
• Trial date.
• Stipulated dismissal.
• Consent judgment.
• Settlement-related dismissal.

A settlement would likely define an agreed launch date, supply rights, or other commercial conditions. Hatch-Waxman settlements can include licensed entry, authorized generic terms, or restrictions tied to patent expiry. Any settlement involving delayed entry may also require review under the Federal Trade Commission’s pharmaceutical-settlement reporting regime.

No biosimilar litigation analysis applies to this case. Pomalyst is a small molecule, and MSN’s regulatory route is an ANDA rather than a 351(k) application.

What generic launch scenarios exist for MSN?

MSN’s commercial launch options can be ranked as follows:

Scenario	Commercial result	Risk level
Celgene wins on enforceable blocking claims	FDA approval remains delayed until patent protection ends	Highest risk for MSN
MSN wins on invalidity or noninfringement	Potential at-risk launch after approval	High litigation exposure
Settlement with agreed early entry	Predictable launch date, subject to settlement terms	Moderate
Skinny-label approval	Entry limited to nonpatented indications or uses	Moderate to high
Authorized generic arrangement	Entry may occur under Celgene-controlled supply terms	Lower litigation risk
Dismissal without disclosed terms	Launch timing cannot be inferred from dismissal alone	High analytical risk

An at-risk launch could expose MSN to damages if the asserted patents are later upheld. Generic firms commonly balance that risk against expected price erosion, first-filer advantages, and the value of being among the first entrants.

What revenue exposure does Pomalyst litigation create?

Pomalyst has been a material oncology product for Celgene and Bristol Myers Squibb. Generic entry would likely produce rapid price erosion, particularly if multiple manufacturers launch simultaneously. The effect would depend on:

• Number of approved generic suppliers.
• Whether MSN is first to launch.
• Whether an authorized generic is present.
• Strength of the remaining indication set.
• Pomalyst’s use in combination regimens.
• Wholesaler and payer substitution policies.
• Availability of alternative immunomodulatory therapies.

A single generic entrant may initially preserve a meaningful price premium. Multiple generic entrants generally accelerate discounting and reduce branded volume. Method-of-use patents can delay generic substitution for specific indications but rarely preserve the entire branded market if the core product becomes available.

How does Pomalyst compare with Revlimid and Thalomid patent estates?

Product	Active ingredient	Regulatory pathway for generics	Patent profile
Pomalyst	Pomalidomide	ANDA	Later-generation immunomodulatory product with layered treatment and formulation claims
Revlimid	Lenalidomide	ANDA	Extensive patent and settlement history; major exposure to generic entry
Thalomid	Thalidomide	ANDA	Older compound with earlier core patent expiry and safety-distribution controls

Pomalyst benefits from a newer product lifecycle than Thalomid but has a smaller commercial market than Revlimid. Its patent estate is more dependent on later treatment, dosing, and formulation claims than on long-lived core compound protection.

Key Takeaways

• Celgene v. MSN Laboratories, Case No. 2:22-cv-01993, is a Hatch-Waxman action involving generic pomalidomide capsules.
• Pomalyst is a small-molecule product, so the case concerns an ANDA and Paragraph IV certifications, not biosimilar approval.
• The dispute implicates Celgene’s layered patent estate covering pomalidomide, formulations, dosing, and multiple-myeloma treatment methods.
• The 2022 filing triggered the statutory 30-month FDA approval stay unless terminated earlier by judgment, settlement, or court order.
• The commercial outcome depends on the asserted patent claims, not the full set of Orange Book-listed patents.
• Method-of-use claims may be vulnerable to skinny-label and induced-infringement defenses.
• A settlement could establish an agreed MSN launch date without a merits ruling.
• Generic entry would create substantial Pomalyst revenue and pricing exposure, particularly if multiple manufacturers launch.

FAQs About Celgene v. MSN Laboratories and Pomalyst Generic Entry

Is MSN Laboratories seeking approval for generic Pomalyst?

Yes. The action concerns MSN’s ANDA for generic pomalidomide capsules, the active ingredient in Pomalyst.

Is Pomalyst protected by a biologic exclusivity period?

No. Pomalyst is a small-molecule drug. Its generic approval pathway is the ANDA process, and its principal barriers are Orange Book patents and any remaining statutory exclusivity.

Can MSN launch generic pomalidomide before every Pomalyst patent expires?

Potentially. MSN could launch after prevailing in litigation, reaching a settlement, using a noninfringing label, or obtaining approval after the relevant blocking patents expire. The expiration of one patent does not necessarily remove all market barriers.

Does a Paragraph IV filing mean that generic pomalidomide is FDA-approved?

No. A Paragraph IV certification challenges patent protection. FDA approval remains subject to statutory exclusivity, patent-stay rules, technical review, and final regulatory action.

What is the main commercial risk to Celgene from MSN’s case?

The primary risk is loss of exclusivity for Pomalyst capsules through an early generic launch. The magnitude depends on MSN’s launch timing, the number of competing ANDA applicants, settlement terms, and whether an authorized generic enters the market.

References

1. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations (Orange Book).
2. U.S. Food and Drug Administration. (2013). Pomalyst (pomalidomide) prescribing information.
3. United States District Court for the District of New Jersey. (2022). Celgene Corporation v. MSN Laboratories Private Limited, No. 2:22-cv-01993.
4. United States Code. (2023). 21 U.S.C. § 355(j), abbreviated applications for new drugs.
5. United States Code. (2023). 35 U.S.C. § 271(e)(2), infringement based on submission of an abbreviated new drug application.
6. U.S. Patent and Trademark Office. (2024). Patent Center and Patent Examination Data System records for Celgene pomalidomide patent families.